

19 October 2023
ASX Announcement

ADALTA SELECTED FOR EXTENDED ORAL PRESENTATION AT MPGPCR 2023 PHARMACOLOGY CONFERENCE

MELBOURNE Australia, 19 October 2023: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel protein and cell therapeutic products from its i-body platform, is pleased to announce that an abstract describing development and clinically effective dose estimation for lead product AD-214 has been accepted as a poster and selected for oral presentation at the 11th Molecular Pharmacology of GPCRs meeting in Melbourne, 15-17 November 2023.

AdAlta's poster, to be presented by Senior Scientist Dr Jason Lynch, is one of just four selected for oral presentation at this meeting.

At MPGPCR 2023, key presentations from leading international researchers will showcase new molecular insights, the latest tools and technologies that are changing our understanding of G-protein coupled receptor (GPCR) function, and translation of basic research into the clinic. GPCRs are a very important class of drug targets that historically have been difficult for antibodies to address.

AD-214 uses AdAlta's i-body® technology to target a GPCR known as CXCR4 with antibody-like precision. AD-214 is the only product targeting CXCR4 for fibrotic diseases such as Idiopathic Pulmonary Fibrosis and is believed to be the most advanced antibody-like product in active development for IPF, highlighting the power of the i-body® platform to do what antibodies cannot.

Presentation details

Time and date: Poster: 5:00pm AEST on Wednesday 15 November 2023.
Presentation: 12:30pm AEST on Thursday 16 November 2023.

Presentation topic: Poster: "*Clinical dose estimation for anti-CXCR4 i-body-Fc fusion AD-214 for the treatment of fibrotic disease*" will focus on studies and dose simulations supporting the efficacy of AD-214's target intravenous product and the feasibility of an enhanced subcutaneous product

Presentation: "*Anti CXCR4 i-body-Fc fusion AD-214 for the treatment of fibrotic diseases*" will focus on the discovery and characterisation of AD-214, the clinical pharmacology observed in Phase I trials and the clinical dosing simulation these enabled.

Conference details: MPGPCR23 will be held at the Monash Institute of Pharmaceutical Sciences, Melbourne, Australia.
Registrations close 25 October 2023. Further details can be found here: <https://www.monash.edu/mips/news-events/mpgpcr-2023>

Authorised for lodgement by:
Tim Oldham
CEO and Managing Director
October 2023

Shareholders: please update your communication preferences

We encourage shareholders to update their share registry preferences to receive all communications electronically. Doing so helps us communicate with you in a time-efficient manner on important matters, while minimising our mail costs and environmental impact.



Simply [click here](#) or scan the QR code and follow the instructions.

Not a shareholder, but want to keep across our progress? [Click here](#) to subscribe to our updates using the Stay in Touch form.

Notes to Editors

About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: <https://adalta.com.au>

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director

Tel: +61 403 446 665

E: t.oldham@adalta.com.au

Media

IR Department

Tel: +61 411 117 774

E: jane.lope@irdepartment.com.au